Generation Bio (GBIO) Stock Price, News & Analysis

Company Overview

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $0.40 to $0.44
• 50-Day Range: $0.43 to $0.99
• 52-Week Range: $0.40 to $4.65
• Volume: 365,901 shs
• Average Volume: 258,382 shs
• Market Capitalization: $27.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.33
• Consensus Rating: Buy

Generation Bio Stock Analysis - MarketRank™

Generation Bio scored higher than 86% of companies evaluated by MarketBeat, and ranked 147th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Generation Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Generation Bio has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Generation Bio are expected to grow in the coming year, from ($1.75) to ($0.95) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Generation Bio is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Generation Bio is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Generation Bio has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.67% of the float of Generation Bio has been sold short.

Short Interest Ratio / Days to Cover

Generation Bio has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Generation Bio has recently decreased by 34.38%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Generation Bio does not currently pay a dividend.

Dividend Growth

Generation Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.67% of the float of Generation Bio has been sold short.

Short Interest Ratio / Days to Cover

Generation Bio has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Generation Bio has recently decreased by 34.38%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.43

News Sentiment

Generation Bio has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Generation Bio this week, compared to 1 article on an average week.

Search Interest

2 people have searched for GBIO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Generation Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 5.0 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Generation Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $203,209.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

21.10% of the stock of Generation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.22% of the stock of Generation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GBIO Stock Analysis - Frequently Asked Questions

How have GBIO shares performed this year?

Generation Bio's stock was trading at $1.06 on January 1st, 2025. Since then, GBIO shares have decreased by 61.8% and is now trading at $0.4050.
View the best growth stocks for 2025 here.

How were Generation Bio's earnings last quarter?

Generation Bio Co. (NASDAQ:GBIO) issued its quarterly earnings results on Wednesday, March, 19th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.01. The company had revenue of $4.19 million for the quarter, compared to the consensus estimate of $2.92 million. Generation Bio had a negative net margin of 782.86% and a negative trailing twelve-month return on equity of 104.85%.

When did Generation Bio IPO?

Generation Bio (GBIO) raised $126 million in an initial public offering on Friday, June 12th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Generation Bio's major shareholders?

Generation Bio's top institutional investors include Price T Rowe Associates Inc. MD (13.89%), Jefferies Financial Group Inc. (3.39%), Jefferies Financial Group Inc. (3.39%) and Renaissance Technologies LLC (1.44%). Insiders that own company stock include Phillip Samayoa, Antoinette Paone and Dannielle Appelhans.
View institutional ownership trends.

How do I buy shares of Generation Bio?

Shares of GBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Generation Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Generation Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Visa (V) and Home Depot (HD).

Company Calendar

• Last Earnings: 3/19/2025
• Today: 3/31/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GBIO
• CIK: 1733294
• Web: generationbio.com
• Phone: 617-655-7500
• Fax: N/A
• Employees: 150
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.33
• High Stock Price Target: $9.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +1,710.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-126,610,000.00
• Net Margins: -782.86%
• Pretax Margin: -782.86%
• Return on Equity: -104.85%
• Return on Assets: -49.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.34
• Quick Ratio: 6.34

Sales & Book Value

• Annual Sales: $19.89 million
• Price / Sales: 1.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.07 per share
• Price / Book: 0.13

Miscellaneous

• Outstanding Shares: 67,008,000
• Free Float: 52,700,000
• Market Cap: $27.14 million
• Optionable: Optionable
• Beta: 2.72